Joe-elie Salem is an associate professor at Sorbonne Université as executive assistant director of cardio-metabolism at the Clinical Investigation Center Paris Est, Paris, France. Dr Salem is particularly interested in cardiovascular pharmacology, cardio-immunology, heart failure and drug-induced arrhythmias applied to cardio-oncology. His current focus has been creating a cardio-oncology programme at Sorbonne Université and fostering research in this field, in collaboration with Vanderbilt, where he has an adjunct associate professor position.
Dr Salem obtained his cardiovascular MD certification at Paris V and VI, Sorbonne, with additional diplomas in cardiovascular imaging (echocardiography, CT and MRI) and clinical pharmacology over 2003 to 2014. He defended his PhD thesis in cardiovascular clinical pharmacology at Sorbonne. His PhD research, undertaken from 2013 to 2016, focused on the development of new tools to predict deleterious drug effects on cardiac repolarisation (i.e., drug-induced long QT syndrome, 2 patents on this topic). From 2013 to 2017, Dr Salem was assistant professor of pharmacology at the Clinical Investigation Center at Hopitaux de Paris and Pierre and Marie Curie University, Sorbonne. This experience led him to conceive, participate and assist in the coordination of numerous translational research programs and clinical trials, mainly in the field of cardio-metabolism and pharmacology.
From 2017 to 2018, Dr Salem has been a clinical cardio-oncology fellow in cardio-oncology and a postdoctoral fellow in clinical pharmacology at Vanderbilt (Dr J Moslehi and Dr D Roden, Nashville, USA). During this year at Vanderbilt, his first research focus was on cardio-oncology, particularly cardio-immunology and influence of hormonotherapy on arrhythmia risk. His other focus was on precision medicine, notably using DNA linked electronic health record cohorts seeking for genetic variants associated with cardiac arrhythmias.